The Candidates List: Targets and Possible Therapies for Squamous Cell Carcinoma of the Lung
This article was originally published in RPM Report
Executive Summary
The Friends of Cancer Research has identified 16 potential molecular targets and nearly two dozen drugs in development for use in squamous cell carcinoma of the lung. Organizers of a master protocol registrational trial for SCCL hope to select four therapies to test when the study launches in 2014.
You may also be interested in...
Landmark Trial for Personalized Medicine Coming Soon: NGS Approval May Be One Offshoot of Lung Cancer “Master Protocol”
A Friends of Cancer Research/Brookings proposal for a multi-drug, multi-sponsor registrational study of targeted cancer drugs is moving forward. Squamous cell lung cancer will be the initial indication. If successful, the study could lead to rapid final development of several targeted therapies, a potential route to FDA approval of NextGen Sequencing in oncology—and broad adoption of the “master protocol” model.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.